Oruka Therapeutics
ORKA
105 hedge funds and large institutions have $876M invested in Oruka Therapeutics in 2025 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 31 increasing their positions, 22 reducing their positions, and 8 closing their positions.
300% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 8
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
127% more capital invested
Capital invested by funds: $386M → $876M (+$490M)
41% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 22
29.69% more ownership
Funds ownership: 91.96% → 121.65% (+30%)
30% more funds holding
Funds holding: 81 → 105 (+24)
84% less call options, than puts
Call options by funds: $497K | Put options by funds: $3.03M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$39.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$24.3M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$19.8M |
| 4 |
PA
Perceptive Advisors
New York
|
+$18.8M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$6.54M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
-$2.11M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$1.85M |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$1.81M |
| 5 |
CCC
Cable Car Capital
San Francisco,
California
|
-$1.48M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SS
101
SBI Securities
Tokyo,
Japan
| $115 | +$59 | +4 | +200% |
|
|
AF
102
Allworth Financial
Folsom,
California
| $97 | – | – | – |
|
|
IA
103
IFP Advisors
Tampa,
Florida
| $58 | +$44 | +3 | New |
|
104
Osaic Holdings
Scottsdale,
Arizona
| $19 | – | – | – |
|
105
CIBC Private Wealth Group
Atlanta,
Georgia
| $19 | +$15 | +1 | New |
|
|
FLSM
106
Frazier Life Sciences Management
Palo Alto,
California
| – | -$6.54M | -583,327 | Closed |
|
|
SCM
107
Silverarc Capital Management
Boston,
Massachusetts
| – | -$1.85M | -165,389 | Closed |
|
|
IC
108
Ikarian Capital
Dallas,
Texas
| – | -$769K | -68,574 | Closed |
|
109
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$503K | -33,962 | Closed |
|
|
BFM
110
Boothbay Fund Management
New York
| – | -$213K | -19,003 | Closed |
|
111
Renaissance Technologies
New York
| – | -$156K | -13,900 | Closed |
|
112
Millennium Management
New York
| – | -$138K | -12,326 | Closed |
|
|
CIAM
113
Caitong International Asset Management
Hong Kong
| – | -$11 | -1 | Closed |
|
ORKA Hedge Fund Activity: Q3 2025 in Review
105 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q3 2025, worth a combined $876M — up 127% from $386M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new ORKA positions and 8 closed out — a net gain of 24 holders — while 31 added to existing stakes and 22 trimmed.
The largest buyer was Viking Global Investors, opening a new position worth an estimated $39.5M. The largest seller was Frazier Life Sciences Management, exiting entirely with an estimated $6.54M sold.
- 105 institutional investors held Oruka Therapeutics (ORKA) as of Q3 2025, up from 81 in Q2 2025.
- Funds reported $876M of Oruka Therapeutics stock for Q3 2025, up 127% quarter-over-quarter.
- 32 funds opened new Oruka Therapeutics positions in Q3 2025 and 8 closed out, a net change of +24 holders.
- The largest Oruka Therapeutics buyer in Q3 2025 was Viking Global Investors, an estimated $39.5M added.
- The largest Oruka Therapeutics seller in Q3 2025 was Frazier Life Sciences Management, an estimated $6.54M sold.
Based on aggregated 13F filings for Q3 2025.